Aster DM Healthcare
- Home ›
- IN ›
- Healthcare
Aster DM Healthcare Limited operates as a healthcare company in the Middle East, India, and the Far East. The last earnings update was 95 days ago. More info.
Add to Portfolio Compare Print
ASTERDM Share Price and Events
7 Day Returns
1 Year Returns
ASTERDM Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Aster DM Healthcare (ASTERDM) | -8.9% | -16.1% | -16.9% | -31.9% | - | - |
| IN Healthcare | -2.3% | -8.7% | -4.1% | -10.9% | -15.9% | 21.8% |
| IN Market | -0.1% | -5% | 4.7% | -3.7% | 34.5% | 38.6% |
1 Year Return vs Industry and Market
- ASTERDM underperformed the Healthcare industry which returned -10.9% over the past year.
- ASTERDM underperformed the Market in India which returned -3.7% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Aster DM Healthcare
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Aster DM Healthcare.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 4 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 12.7% |
| Perpetual Growth Rate | 10-Year IN Government Bond Rate | 7.6% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year IN Govt Bond Rate | 7.6% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.68 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.684 (1 + (1- 55%) (40.4%)) |
0.871 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.87 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 7.55% + (0.871 * 5.96%) |
12.74% |
Discounted Cash Flow Calculation for NSEI:ASTERDM using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Aster DM Healthcare is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (INR, Millions) | Source |
Present Value Discounted (@ 12.74%) |
|
|---|---|---|---|
| 2019 | -1,392.00 | Analyst x1 | -1,234.66 |
| 2020 | 3,452.00 | Analyst x1 | 2,715.75 |
| 2021 | 4,736.00 | Analyst x1 | 3,304.77 |
| 2022 | 5,883.71 | Est @ 24.23% | 3,641.58 |
| 2023 | 7,015.06 | Est @ 19.23% | 3,851.05 |
| 2024 | 8,118.17 | Est @ 15.72% | 3,952.91 |
| 2025 | 9,195.66 | Est @ 13.27% | 3,971.46 |
| 2026 | 10,258.28 | Est @ 11.56% | 3,929.63 |
| 2027 | 11,320.43 | Est @ 10.35% | 3,846.36 |
| 2028 | 12,397.32 | Est @ 9.51% | 3,736.15 |
| Present value of next 10 years cash flows | ₹31,715.00 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= ₹12,397.32 × (1 + 7.55%) ÷ (12.74% – 7.55%) |
₹256,746.20 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= ₹256,746.20 ÷ (1 + 12.74%)10 |
₹77,375.03 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= ₹31,715.00 + ₹77,375.03 |
₹109,090.03 |
| Equity Value per Share (INR) |
= Total value / Shares Outstanding
= ₹109,090.03 / 501.52 |
₹217.52 |
| Calculation | Result | |
|---|---|---|
| Value per share (INR) | From above. | ₹217.52 |
| Current discount | Discount to share price of
₹128.00
= -1 x (₹128.00 - ₹217.52) / ₹217.52 |
41.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Aster DM Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Aster DM Healthcare's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Aster DM Healthcare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Aster DM Healthcare's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in INR | ₹6.38 |
| NSEI:ASTERDM Share Price ** | NSEI (2019-05-17) in INR | ₹128 |
| India Healthcare Industry PE Ratio | Median Figure of 23 Publicly-Listed Healthcare Companies | 22.83x |
| India Market PE Ratio | Median Figure of 2,758 Publicly-Listed Companies | 15.12x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Aster DM Healthcare.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NSEI:ASTERDM Share Price ÷ EPS (both in INR) = 128 ÷ 6.38 |
20.05x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aster DM Healthcare is good value based on earnings compared to the IN Healthcare industry average.
- Aster DM Healthcare is overvalued based on earnings compared to the India market.
Price based on expected Growth
Does
Aster DM Healthcare's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 20.05x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts |
32.1%per year |
| India Healthcare Industry PEG Ratio | Median Figure of 5 Publicly-Listed Healthcare Companies | 1.82x |
| India Market PEG Ratio | Median Figure of 559 Publicly-Listed Companies | 1.25x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 20.05x ÷ 32.1% |
0.62x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aster DM Healthcare is good value based on expected growth next year.
Price based on value of assets
What value do investors place on
Aster DM Healthcare's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in INR | ₹59.97 |
| NSEI:ASTERDM Share Price * | NSEI (2019-05-17) in INR | ₹128 |
| India Healthcare Industry PB Ratio | Median Figure of 33 Publicly-Listed Healthcare Companies | 1.9x |
| India Market PB Ratio | Median Figure of 3,638 Publicly-Listed Companies | 1.02x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NSEI:ASTERDM Share Price ÷ Book Value per Share (both in INR) = 128 ÷ 59.97 |
2.13x |
* Primary Listing of Aster DM Healthcare.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aster DM Healthcare is overvalued based on assets compared to the IN Healthcare industry average.
Value checks
We assess Aster DM Healthcare's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) Aster DM Healthcare has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Aster DM Healthcare's earnings growth is expected to exceed the low risk savings rate of 7.6%.
Growth vs Market Checks
- Aster DM Healthcare's earnings growth is expected to exceed the India market average.
- Aster DM Healthcare's revenue growth is expected to exceed the India market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NSEI:ASTERDM Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts | 32.1% |
| NSEI:ASTERDM Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts | 12.2% |
| India Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 39.9% |
| India Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 12.5% |
| India Market Earnings Growth Rate | Market Cap Weighted Average | 16.8% |
| India Market Revenue Growth Rate | Market Cap Weighted Average | 10.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 100,274 | 10,151 | 6,027 | 4 |
| 2020-03-31 | 90,080 | 8,266 | 4,187 | 4 |
| 2019-03-31 | 79,657 | 6,616 | 3,058 | 4 |
| Date (Data in INR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 75,460 | 3,139 | |
| 2018-09-30 | 72,102 | 3,687 | |
| 2018-06-30 | 69,394 | 3,582 | |
| 2018-03-31 | 67,212 | 5,374 | 2,689 |
| 2017-03-31 | 59,313 | 3,608 | 1,018 |
| 2016-03-31 | 52,499 | 2,027 | -590 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
All data from Aster DM Healthcare Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-03-31 | 10.97 | 11.90 | 10.03 | 2.00 |
| 2020-03-31 | 7.92 | 8.30 | 7.53 | 2.00 |
| 2019-03-31 | 5.47 | 6.10 | 4.84 | 2.00 |
| Date (Data in INR Millions) | EPS * |
|---|---|
| 2018-12-31 | 6.38 |
| 2018-09-30 | 7.60 |
| 2018-06-30 | 7.53 |
| 2018-03-31 | 5.75 |
| 2017-03-31 | 2.20 |
| 2016-03-31 | -1.35 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Aster DM Healthcare's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the India market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the India market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Aster DM Healthcare has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Aster DM Healthcare performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Aster DM Healthcare has delivered over 20% year on year earnings growth in the past 5 years.
- Aster DM Healthcare's 1-year earnings growth exceeds its 5-year average (37.9% vs 24.3%)
- Aster DM Healthcare's earnings growth has exceeded the IN Healthcare industry average in the past year (37.9% vs -4.9%).
Earnings and Revenue History
All data from Aster DM Healthcare Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in INR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 75,459.71 | 3,139.26 | 4,771.91 | |
| 2018-09-30 | 72,101.51 | 3,687.36 | 4,543.61 | |
| 2018-06-30 | 69,393.71 | 3,582.06 | 4,390.91 | |
| 2018-03-31 | 67,211.61 | 2,688.76 | 4,224.71 | |
| 2017-03-31 | 59,312.87 | 1,017.60 | 4,120.02 | |
| 2016-03-31 | 52,498.90 | -590.15 | 2,994.77 | |
| 2015-03-31 | 38,758.43 | 1,326.92 | 1,798.06 | |
| 2014-03-31 | 28,711.45 | 1,777.83 | 1,220.98 | |
| 2013-03-31 | 19,217.42 | 917.81 | 885.93 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Aster DM Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Aster DM Healthcare used its assets more efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Aster DM Healthcare has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Aster DM Healthcare's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Aster DM Healthcare has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Aster DM Healthcare's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Aster DM Healthcare's finances.
The net worth of a company is the difference between its assets and liabilities.
- Aster DM Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Aster DM Healthcare's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Aster DM Healthcare Company Filings, last reported 4 months ago.
| Date (Data in INR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 34,026.50 | 25,934.70 | 3,438.10 |
| 2018-09-30 | 34,026.50 | 25,934.70 | 3,438.10 |
| 2018-06-30 | 31,900.32 | 23,641.01 | 2,877.41 |
| 2018-03-31 | 31,900.32 | 23,641.01 | 2,877.41 |
| 2017-03-31 | 22,506.77 | 27,592.72 | 1,663.82 |
| 2016-03-31 | 5,966.65 | 33,252.59 | 3,014.62 |
| 2015-03-31 | 22,461.33 | 10,927.61 | 2,854.33 |
| 2014-03-31 | 13,705.81 | 8,858.55 | 3,247.36 |
| 2013-03-31 | 11,423.73 | 5,046.46 | 2,008.72 |
- Aster DM Healthcare's level of debt (76.2%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (60.3% vs 76.2% today).
- Debt is well covered by operating cash flow (20.7%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 3.3x coverage).
Financial health checks
We assess Aster DM Healthcare's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Aster DM Healthcare has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Aster DM Healthcare's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
₹2,000 of
Aster DM Healthcare
shares you are expected to receive
₹0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Aster DM Healthcare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Aster DM Healthcare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| India Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.7% |
| India Market Average Dividend Yield | Market Cap Weighted Average of 1398 Stocks | 1.4% |
| India Minimum Threshold Dividend Yield | 10th Percentile | 0.3% |
| India Bottom 25% Dividend Yield | 25th Percentile | 0.6% |
| India Top 25% Dividend Yield | 75th Percentile | 2.1% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in ₹) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-03-31 | 0.00 | 1.00 |
| 2020-03-31 | 0.00 | 1.00 |
| 2019-03-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Aster DM Healthcare has not reported any payouts.
- Unable to verify if Aster DM Healthcare's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Aster DM Healthcare's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.3%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Aster DM Healthcare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Aster DM Healthcare has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | ₹0 |
| AGE | 65 |
| TENURE AS CEO | 4.4 years |
CEO Bio
Dr. Mandayapurath Azad Moopen, M.D. is the Chairman of Aster DM Healthcare Ltd and has been its Managing Director since December 1, 2014. Dr. Moopen is Founder of Aster DM Healthcare Limited. He is a gold medalist in Medicine and a post graduate in General Medicine from University of Calicut, Kerala, India and a diploma holder in Tuberculosis and Chest Diseases from Delhi University, Delhi, India. He is responsible for Company’s overall business operations and is responsible for setting forth the group strategy and vision. He also serves as a director of NORKA Roots. He has set up Dr. Moopen’s Foundation, a charitable foundation for extending healthcare charitable benefits to the less privileged. He has been a Director of Company since its incorporation. He has been honoured by the Government of India with the Padma Shri Award in 2011 and the Pravasi Bharatiya Samman in 2010. He has also been conferred the Best Doctor Award by the Government of Kerala in 2009. He has also received the Arab Health Award from the Arab Health Forum in 2010, the Arabian Business Achievement Award from the ITP Publishing Group in 2010 and the Healthcare CEO of the Year Award at the CEO Middle East Awards 2015. His Directorship in Indian companies includes DM Med City Hospitals (India) Private Limited, Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited, Malabar Institute of Medical Sciences Limited, Norka Roots, Wayanad Infrastructure Private Limited. His Directorship in Foreign Companies Includes AAQ Healthcare Investment LLC, Affinity Holdings Private Limited, Al Rafa Holdings Limited, Al Rafa Investments Limited, Al Rafa Medical Centre LLC, Al Raffah Hospital LLC (Muscat), Al Raffah Medical Centre LLC, Al Raffah Pharmacies Group LLC, Al Shafar Pharmacy LLC, Alfa Drug Store LLC, Aries Holdings FZC, Aster Al Shafar Pharmacies Group LLC, Aster DM Healthcare (SPC), Aster DM Healthcare FZC, Aster DM Healthcare INC, Aster Day Surgery Centre LLC, Aster Medical Centre LLC, Aster Opticals LLC, Aster Pharmacies Group LLC, Aster Pharmacy LLC, Credence High School LLC, Dar Al Shifa Medical Centre LLC, DM Healthcare LLC, DM Pharmacies LLC, Dr. Moopens Healthcare Management Services LLC, Dr. Moopens Healthcare Management Services WLL, Dr. Moopens Medical Clinic LLC, Eurohealth Systems FZ LLC, Ibn Al Haitham Pharmacy LLC, Med Shop Drugs Store LLC, Medcare Hospital LLC, Medshop Garden Pharmacy LLC, Modern Dar Al Shifa Pharmacy LLC, New Aster Pharmacy DMCC, Rafa Pharmacy LLC, Shindhagha Pharmacy LLC, Union Investments Private Limited, Union Pharmacy LLC, Zabeel Pharmacy LLC (under winding up). He also holds Partnership in Learning Chain Education Management LLP and Endeavu Infra Developers LLP. He holds Trusteeship in Aster DM Foundation, DM Education and Research Foundation, Dr. Moopen’s Family Foundation, MIMS Research Foundation, N & M Foundation, DM Healthcare Foundation INC.
CEO Compensation
- Insufficient data for Mandayapurath to compare compensation growth.
- Mandayapurath's remuneration is lower than average for companies of similar size in India.
Management Team Tenure
Average tenure and age of the Aster DM Healthcare management team in years:
- The tenure for the Aster DM Healthcare management team is about average.
Management Team
Mandayapurath Moopen
Founder
65
4.4 yrs
Sreenath Reddy
Chief Financial Officer
44
6.5 yrs
Harish Pillai
CEO of India
50
6 yrs
Nitish Shetty
Chief Executive Officer of Aster CMI Hospital
47
4.6 yrs
Vinod Ramanunni
Chief Business Development Officer
52
Chandil Gunashekara
Chief Executive Officer of Aster Aadhar
40
Veneeth Purushotaman
Group Chief Information Officer
1.3 yrs
Puja Aggarwal
Company Secretary & Compliance Officer
0.8 yrs
Dalia Aziz
Chief Marketing & Communications Officer
47
1.9 yrs
Farhat Siddiqi
Group Chief Human Resources Officer
42
1.9 yrs
Board of Directors Tenure
Average tenure and age of the Aster DM Healthcare board of directors in years:
- The tenure for the Aster DM Healthcare board of directors is about average.
Board of Directors
T. Wilson
Non-Executive Director
57
10.1 yrs
Maniedath Nambiar
Non-Executive Independent Director
₹800K
68
4.1 yrs
Mandayapurath Moopen
Founder
65
Alisha Moopen
Non-Executive Director
36
5.7 yrs
Anoop Moopen
Non-Executive Director
41
10.1 yrs
Shamsudheen Bin Mohideen Mammu Haji
Non-Executive Director
55
3.7 yrs
Ravi Prasad
Non-Executive Independent Director
₹800K
57
4.1 yrs
Dan Snyder
Non-Executive Independent Director
₹500K
63
4.1 yrs
Suresh Kumar
Non-Executive Independent Director
₹800K
67
3.7 yrs
Daniel Mintz
Non-Executive Director
56
2.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (₹) | Value (₹) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 28. Jan 19 | Buy | Mandayapurath Moopen | Individual | 24. Jan 19 | 25. Jan 19 | 59,746 | ₹161.55 | ₹9,651,978 | ||
| 24. Jan 19 | Buy | Mandayapurath Moopen | Individual | 23. Jan 19 | 23. Jan 19 | 30,000 | ₹163.47 | ₹4,904,100 | ||
| 22. Jan 19 | Buy | Mandayapurath Moopen | Individual | 21. Jan 19 | 21. Jan 19 | 13,254 | ₹164.29 | ₹2,177,500 | ||
| 21. Jan 19 | Buy | Mandayapurath Moopen | Individual | 17. Jan 19 | 18. Jan 19 | 60,000 | ₹165.10 | ₹9,905,997 | ||
| 17. Jan 19 | Buy | Mandayapurath Moopen | Individual | 16. Jan 19 | 16. Jan 19 | 12,000 | ₹165.42 | ₹1,985,040 | ||
| 16. Jan 19 | Buy | Mandayapurath Moopen | Individual | 15. Jan 19 | 15. Jan 19 | 16,490 | ₹165.30 | ₹2,725,775 | ||
| 14. Jan 19 | Buy | Mandayapurath Moopen | Individual | 10. Jan 19 | 11. Jan 19 | 65,510 | ₹162.51 | ₹10,646,059 | ||
| 10. Jan 19 | Buy | Mandayapurath Moopen | Individual | 09. Jan 19 | 09. Jan 19 | 19,102 | ₹164.45 | ₹3,141,323 | ||
| 08. Jan 19 | Buy | Mandayapurath Moopen | Individual | 07. Jan 19 | 07. Jan 19 | 18,898 | ₹164.64 | ₹3,111,366 | ||
| 05. Jan 19 | Buy | Mandayapurath Moopen | Individual | 04. Jan 19 | 04. Jan 19 | 14,996 | ₹160.45 | ₹2,406,107 | ||
| 04. Jan 19 | Buy | Mandayapurath Moopen | Individual | 03. Jan 19 | 03. Jan 19 | 14,207 | ₹160.26 | ₹2,276,813 | ||
| 02. Jan 19 | Buy | Mandayapurath Moopen | Individual | 31. Dec 18 | 01. Jan 19 | 69,000 | ₹156.64 | ₹10,808,370 | ||
| 03. Jan 19 | Buy | Mandayapurath Moopen | Individual | 02. Jan 19 | 02. Jan 19 | 40,000 | ₹159.05 | ₹6,362,000 | ||
| 31. Dec 18 | Buy | Mandayapurath Moopen | Individual | 27. Dec 18 | 27. Dec 18 | 60,000 | ₹150.71 | ₹9,042,599 | ||
| 27. Dec 18 | Buy | Mandayapurath Moopen | Individual | 26. Dec 18 | 26. Dec 18 | 60,000 | ₹149.94 | ₹8,996,399 | ||
| 26. Dec 18 | Buy | Mandayapurath Moopen | Individual | 24. Dec 18 | 24. Dec 18 | 60,000 | ₹152.02 | ₹9,121,197 | ||
| 24. Dec 18 | Buy | Mandayapurath Moopen | Individual | 20. Dec 18 | 20. Dec 18 | 60,000 | ₹153.25 | ₹9,194,996 | ||
| 21. Dec 18 | Buy | Mandayapurath Moopen | Individual | 19. Dec 18 | 19. Dec 18 | 39,297 | ₹154.58 | ₹6,074,528 | ||
| 19. Dec 18 | Buy | Mandayapurath Moopen | Individual | 18. Dec 18 | 18. Dec 18 | 60,000 | ₹152.22 | ₹9,133,200 | ||
| 18. Dec 18 | Buy | Mandayapurath Moopen | Individual | 17. Dec 18 | 17. Dec 18 | 60,000 | ₹151.24 | ₹9,074,400 | ||
| 17. Dec 18 | Buy | Mandayapurath Moopen | Individual | 13. Dec 18 | 14. Dec 18 | 78,500 | ₹152.19 | ₹11,947,270 | ||
| 13. Dec 18 | Buy | Mandayapurath Moopen | Individual | 12. Dec 18 | 12. Dec 18 | 39,000 | ₹151.78 | ₹5,919,419 | ||
| 12. Dec 18 | Buy | Mandayapurath Moopen | Individual | 11. Dec 18 | 11. Dec 18 | 39,341 | ₹150.54 | ₹5,922,392 | ||
| 11. Dec 18 | Buy | Mandayapurath Moopen | Individual | 10. Dec 18 | 10. Dec 18 | 40,000 | ₹148.34 | ₹5,933,599 | ||
| 10. Dec 18 | Buy | Mandayapurath Moopen | Individual | 30. Nov 18 | 07. Dec 18 | 146,613 | ₹149.38 | ₹21,901,467 | ||
| 01. Dec 18 | Buy | Mandayapurath Moopen | Individual | 29. Nov 18 | 30. Nov 18 | 49,046 | ₹148.00 | ₹7,134,993 | ||
| 07. Dec 18 | Buy | Ahamed Moopan | Individual | 26. Nov 18 | 26. Nov 18 | 13,500 | ₹146.96 | ₹1,983,947 | ||
| 05. Oct 18 | Buy | Athif Moopen | Individual | 24. Sep 18 | 26. Sep 18 | 7,846 | ₹156.77 | ₹1,230,000 | ||
| 29. Sep 18 | Buy | Anoop Moopen | Individual | 27. Sep 18 | 27. Sep 18 | 9,216 | ₹159.52 | ₹1,469,055 | ||
| 27. Sep 18 | Buy | Anoop Moopen | Individual | 26. Sep 18 | 26. Sep 18 | 8,688 | ₹159.02 | ₹1,381,586 | ||
| 26. Sep 18 | Buy | Anoop Moopen | Individual | 25. Sep 18 | 25. Sep 18 | 11,150 | ₹154.43 | ₹1,721,461 | ||
| 25. Sep 18 | Buy | Anoop Moopen | Individual | 24. Sep 18 | 24. Sep 18 | 9,200 | ₹159.71 | ₹1,469,349 | ||
| 22. Sep 18 | Buy | Anoop Moopen | Individual | 21. Sep 18 | 21. Sep 18 | 15,258 | ₹160.75 | ₹2,452,786 | ||
| 20. Sep 18 | Buy | Anoop Moopen | Individual | 19. Sep 18 | 19. Sep 18 | 15,888 | ₹161.26 | ₹2,559,141 | ||
| 19. Sep 18 | Buy | Anoop Moopen | Individual | 18. Sep 18 | 18. Sep 18 | 17,300 | ₹162.00 | ₹2,797,848 | ||
| 18. Sep 18 | Buy | Anoop Moopen | Individual | 17. Sep 18 | 17. Sep 18 | 13,100 | ₹162.11 | ₹2,121,990 | ||
| 17. Sep 18 | Buy | Anoop Moopen | Individual | 14. Sep 18 | 14. Sep 18 | 21,257 | ₹163.72 | ₹3,433,102 | ||
| 14. Sep 18 | Buy | Anoop Moopen | Individual | 12. Sep 18 | 12. Sep 18 | 4,243 | ₹165.88 | ₹702,672 | ||
| 09. Jul 18 | Buy | Anoop Moopen | Individual | 02. Jul 18 | 03. Jul 18 | 7,960 | ₹167.12 | ₹1,325,745 | ||
| 07. Jul 18 | Buy | Anoop Moopen | Individual | 02. Jul 18 | 03. Jul 18 | 7,960 | ₹167.12 | ₹1,325,747 | ||
| 30. Jun 18 | Buy | Anoop Moopen | Individual | 28. Jun 18 | 29. Jun 18 | 24,464 | ₹173.43 | ₹3,919,984 | ||
| 22. Jun 18 | Buy | Anoop Moopen | Individual | 20. Jun 18 | 21. Jun 18 | 22,973 | ₹175.24 | ₹4,014,393 | ||
| 22. Jun 18 | Buy | Anoop Moopen | Individual | 20. Jun 18 | 21. Jun 18 | 22,973 | ₹175.24 | ₹4,014,397 | ||
| 20. Jun 18 | Buy | Mandayapurath Moopen | Individual | 11. Jun 18 | 13. Jun 18 | 46,001 | ₹187.04 | ₹8,569,077 | ||
| 20. Jun 18 | Buy | Anoop Moopen | Individual | 12. Jun 18 | 18. Jun 18 | 28,780 | ₹189.34 | ₹5,389,301 | ||
| 12. Jun 18 | Buy | Anoop Moopen | Individual | 11. Jun 18 | 11. Jun 18 | 3,250 | ₹180.19 | ₹585,479 | ||
| 11. Jun 18 | Buy | Mandayapurath Moopen | Individual | 06. Jun 18 | 08. Jun 18 | 63,599 | ₹180.63 | ₹11,458,670 | ||
| 11. Jun 18 | Buy | Anoop Moopen | Individual | 06. Jun 18 | 08. Jun 18 | 95,012 | ₹180.63 | ₹14,679,306 | ||
| 07. Jun 18 | Buy | Anoop Moopen | Individual | 05. Jun 18 | 06. Jun 18 | 57,594 | ₹179.44 | ₹10,153,450 | ||
| 04. Jun 18 | Buy | Anoop Moopen | Individual | 01. Jun 18 | 04. Jun 18 | 41,464 | ₹178.45 | ₹7,383,128 | ||
| 31. May 18 | Buy | Anoop Moopen | Individual | 28. May 18 | 29. May 18 | 20,000 | ₹180.76 | ₹3,607,070 | ||
Management checks
We assess Aster DM Healthcare's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Aster DM Healthcare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Here's What Aster DM Healthcare Limited's (NSE:ASTERDM) P/E Ratio Is Telling Us
We'll look at Aster DM Healthcare Limited's (NSE:ASTERDM) P/E ratio and reflect on what it tells us about the company's share price. … Looking at earnings over the last twelve months, Aster DM Healthcare has a P/E ratio of 22.33. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleWhy Aster DM Healthcare Limited (NSE:ASTERDM) Could Have A Place In Your Portfolio
Attractive stocks have exceptional fundamentals. … In the case of Aster DM Healthcare Limited (NSE:ASTERDM), there's
Simply Wall St - – Full articleIs Aster DM Healthcare Limited (NSE:ASTERDM) Investing Your Capital Efficiently?
Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … Understanding Return On Capital Employed (ROCE). … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.
Simply Wall St - – Full articleSome Aster DM Healthcare (NSE:ASTERDM) Shareholders Are Down 11%
For example, the Aster DM Healthcare Limited (NSE:ASTERDM) share price is down 11% in the last year. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … Even though the Aster DM Healthcare share price is down over the year, its EPS actually improved.
Simply Wall St - – Full articleDoes Aster DM Healthcare Limited's (NSE:ASTERDM) 38% Earnings Growth Reflect The Long-Term Trend?
Assessing Aster DM Healthcare Limited's (NSE:ASTERDM) past track record of performance is an insightful exercise for investors. … Today I will assess ASTERDM's recent performance announced on 31 December 2018 and evaluate these figures to its long-term trend and industry movements. … Commentary On ASTERDM's Past Performance.
Simply Wall St - – Full articleShould You Care About Aster DM Healthcare Limited’s (NSE:ASTERDM) Cash Levels?
If you are currently a shareholder in Aster DM Healthcare Limited (NSE:ASTERDM), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. … I’ve analysed below, the health and outlook of Aster DM Healthcare’s cash flow, which will help you understand the stock from a cash standpoint. … Aster DM Healthcare generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating
Simply Wall St - – Full articleIs Aster DM Healthcare Limited's (NSE:ASTERDM) ROE Of 12% Impressive?
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … To keep the lesson grounded in practicality, we'll use ROE to better understand Aster DM Healthcare Limited (NSE:ASTERDM). … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleThese Factors Make Aster DM Healthcare Limited (NSE:ASTERDM) An Interesting Investment
I've been keeping an eye on Aster DM Healthcare Limited (NSE:ASTERDM) because I'm attracted to its fundamentals. … Looking at the company as a whole, as a potential stock investment, I believe ASTERDM has a lot to offer.
Simply Wall St - – Full articleIs Aster DM Healthcare Limited's (NSE:ASTERDM) Future Growth Already Accounted For In Today's Price?
Aster DM Healthcare Limited (NSE:ASTERDM) is considered a high-growth stock, but its last closing price of ₹160.65 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … View our latest analysis for Aster DM Healthcare? … Aster DM Healthcare is poised for significantly high earnings growth in the near future
Simply Wall St - – Full articleHow Do Aster DM Healthcare Limited’s (NSE:ASTERDM) Returns Compare To Its Industry?
Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … What is Return On Capital Employed (ROCE)? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.
Simply Wall St - – Full articleCompany Info
Description
Aster DM Healthcare Limited operates as a healthcare company in the Middle East, India, and the Far East. It operates hospitals, clinics, pharmacies, diagnostic centers, and retail pharmacies. The company was founded in 1987 and is headquartered in Dubai, the United Arab Emirates.
Details
| Name: | Aster DM Healthcare Limited |
| ASTERDM | |
| Exchange: | NSEI |
| Founded: | 1987 |
| ₹64,194,916,224 | |
| 501,522,783 | |
| Website: | http://asterdmhealthcare.com |
| Address: |
Aster DM Healthcare Limited Tower D - Aspect Tower, 33rd Floor, Dubai, United Arab Emirates |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NSEI | ASTERDM | Equity Shares | National Stock Exchange of India | IN | INR | 22. Feb 2018 | |
| BSE | 540975 | Equity Shares | Mumbai Stock Exchange | IN | INR | 22. Feb 2018 |
Number of employees
Current staff
Industry
| Health Care Facilities | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/19 13:15 |
| End of day share price update: | 2019/05/17 00:00 |
| Last estimates confirmation: | 2019/05/13 |
| Last earnings filing: | 2019/02/13 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
